
### [NCIT:C9087](http://purl.obolibrary.org/obo/NCIT_C9087)
**Label:** Kaposi Sarcoma

**Subclasses:** [NCIT:C5602](http://purl.obolibrary.org/obo/NCIT_C5602) (Anal Kaposi Sarcoma), [NCIT:C4579](http://purl.obolibrary.org/obo/NCIT_C4579) (Corneal Kaposi Sarcoma), [NCIT:C7006](http://purl.obolibrary.org/obo/NCIT_C7006) (Central Nervous System Kaposi Sarcoma), [NCIT:C5842](http://purl.obolibrary.org/obo/NCIT_C5842) (Gallbladder Kaposi Sarcoma), [NCIT:C96059](http://purl.obolibrary.org/obo/NCIT_C96059) (Small Intestinal Kaposi Sarcoma), [NCIT:C5523](http://purl.obolibrary.org/obo/NCIT_C5523) (Prostate Kaposi Sarcoma), [NCIT:C96510](http://purl.obolibrary.org/obo/NCIT_C96510) (Colorectal Kaposi Sarcoma), [NCIT:C96951](http://purl.obolibrary.org/obo/NCIT_C96951) (Extrahepatic Bile Duct Kaposi Sarcoma), [NCIT:C96434](http://purl.obolibrary.org/obo/NCIT_C96434) (Appendix Kaposi Sarcoma), [NCIT:C4578](http://purl.obolibrary.org/obo/NCIT_C4578) (Conjunctival Kaposi Sarcoma), [NCIT:C5363](http://purl.obolibrary.org/obo/NCIT_C5363) (Cardiac Kaposi Sarcoma), [NCIT:C6377](http://purl.obolibrary.org/obo/NCIT_C6377) (Penile Kaposi Sarcoma), [NCIT:C35874](http://purl.obolibrary.org/obo/NCIT_C35874) (Endemic African Kaposi Sarcoma), [NCIT:C35873](http://purl.obolibrary.org/obo/NCIT_C35873) (Iatrogenic Kaposi Sarcoma), [NCIT:C5529](http://purl.obolibrary.org/obo/NCIT_C5529) (Gastric Kaposi Sarcoma), [NCIT:C5706](http://purl.obolibrary.org/obo/NCIT_C5706) (Esophageal Kaposi Sarcoma), [NCIT:C7935](http://purl.obolibrary.org/obo/NCIT_C7935) (Recurrent Kaposi Sarcoma), [NCIT:C27640](http://purl.obolibrary.org/obo/NCIT_C27640) (Transplant-Related Kaposi Sarcoma), [NCIT:C5516](http://purl.obolibrary.org/obo/NCIT_C5516) (Colon Kaposi Sarcoma), [NCIT:C27500](http://purl.obolibrary.org/obo/NCIT_C27500) (Lymphadenopathic Kaposi Sarcoma), [NCIT:C6749](http://purl.obolibrary.org/obo/NCIT_C6749) (Palate Kaposi Sarcoma), [NCIT:C5952](http://purl.obolibrary.org/obo/NCIT_C5952) (Parotid Gland Kaposi Sarcoma), [NCIT:C5550](http://purl.obolibrary.org/obo/NCIT_C5550) (Rectal Kaposi Sarcoma), [NCIT:C9413](http://purl.obolibrary.org/obo/NCIT_C9413) (Kaposi Sarcoma NCI Grade 2), [NCIT:C9414](http://purl.obolibrary.org/obo/NCIT_C9414) (Kaposi Sarcoma NCI Grade 3), [NCIT:C3551](http://purl.obolibrary.org/obo/NCIT_C3551) (Lung Kaposi Sarcoma), [NCIT:C9112](http://purl.obolibrary.org/obo/NCIT_C9112) (Classic Kaposi Sarcoma), [NCIT:C9113](http://purl.obolibrary.org/obo/NCIT_C9113) (Kaposi Sarcoma Related to Immunosuppressive Treatment), [NCIT:C3550](http://purl.obolibrary.org/obo/NCIT_C3550) (Skin Kaposi Sarcoma), [NCIT:C96844](http://purl.obolibrary.org/obo/NCIT_C96844) (Liver Kaposi Sarcoma), 

**Class expressions from DL-Learner:**

- Thing 54.24%
- [NCIT:C53413](http://purl.obolibrary.org/obo/NCIT_C53413) (Malignant Oval Endothelial Cell) 51.79%
- [NCIT:C53405](http://purl.obolibrary.org/obo/NCIT_C53405) (Malignant Spindle Endothelial Cell) 51.79%
- [NCIT:C37092](http://purl.obolibrary.org/obo/NCIT_C37092) (Spindle Endothelial Cell) and [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) 51.79%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40108](http://purl.obolibrary.org/obo/NCIT_C40108) (Borderline Fallopian Tube Mucinous Tumor))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40107](http://purl.obolibrary.org/obo/NCIT_C40107) (Borderline Fallopian Tube Serous Tumor/Atypical Proliferative Serous Tumor))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40104](http://purl.obolibrary.org/obo/NCIT_C40104) (Fallopian Tube Transitional Cell Carcinoma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40103](http://purl.obolibrary.org/obo/NCIT_C40103) (Fallopian Tube Mucinous Adenocarcinoma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40093](http://purl.obolibrary.org/obo/NCIT_C40093) (Ovarian Squamous Cell Carcinoma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40090](http://purl.obolibrary.org/obo/NCIT_C40090) (Ovarian Seromucinous Carcinoma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40086](http://purl.obolibrary.org/obo/NCIT_C40086) (Ovarian Clear Cell Cystadenofibroma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40083](http://purl.obolibrary.org/obo/NCIT_C40083) (Borderline Ovarian Clear Cell Cystadenofibroma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C40082](http://purl.obolibrary.org/obo/NCIT_C40082) (Borderline Ovarian Clear Cell Adenofibroma with Intraepithelial Carcinoma))) 48.66%
- [NCIT:C47834](http://purl.obolibrary.org/obo/NCIT_C47834) (Malignant Endothelial Cell) and (not ([NCIT:C4008](http://purl.obolibrary.org/obo/NCIT_C4008) (Recurrent Gallbladder Carcinoma))) 48.66%


